CytomX Therapeutics (CTMX) FCF Margin (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly FCF Margin came in at 249.06% in Q1 2026, down 20750.0% YoY from N/an in Q1 2025, and up 92.96% on a QoQ basis from 3536.05% in Q4 2025.
CytomX Therapeutics (CTMX) FCF Margin (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of FCF Margin data on file, last reported at 249.06% in Q1 2026.
- Quarterly FCF Margin fell 20750.0% year-over-year to 249.06% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 225.63% (down 17037.0% YoY) and the FY2025 annual result came in at 99.48%, down 3682.0% from the prior year.
- FCF Margin rose to 249.06% in Q1 2026, from 3536.05% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 39.58% in Q1 2023 to a low of 3536.05% in Q4 2025.
- A 5-year average of 334.69% and a median of 80.67% in 2023 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin jumped 50472 bps — and 2025, when it tumbled 348358 bps.
- Tracing CTMX's FCF Margin over 5 years: stood at 7.83% in 2022, then sank by 931 bps to 80.67% in 2023, then soared by 35 bps to 52.47% in 2024, then tumbled by 6639 bps to 3536.05% in 2025, then soared by 93 bps to 249.06% in 2026.
- The last three FCF Margin figures came in at 249.06% (Q1 2026), 3536.05% (Q4 2025), and 258.61% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | -1,274.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,274.19% |
| Mar 31, 2026 | -249.06% |
| Dec 31, 2025 | -3,536.05% |
| Sep 30, 2025 | -258.61% |
| Jun 30, 2025 | -84.57% |
| Mar 31, 2025 | -41.56% |
| Dec 31, 2024 | -52.47% |
| Sep 30, 2024 | -62.06% |
| Jun 30, 2024 | -78.22% |
| Mar 31, 2024 | -63.09% |
| Dec 31, 2023 | -80.67% |
| Sep 30, 2023 | -69.18% |
| Jun 30, 2023 | -103.93% |
| Mar 31, 2023 | 39.58% |
| Dec 31, 2022 | -7.83% |
| Sep 30, 2022 | -307.30% |
| Jun 30, 2022 | -269.58% |
| Mar 31, 2022 | -465.14% |
| Dec 31, 2021 | -282.40% |
| Sep 30, 2021 | -326.13% |